DOCSLIB.ORG

Sgc Stimulators Sgc-Stimulatoren Stimulateurs De Sgc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sgc Stimulators Sgc-Stimulatoren Stimulateurs De Sgc (19) TZZ ¥_T (11) EP 2 637 659 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/427 (2006.01) A61K 31/4439 (2006.01) 18.05.2016 Bulletin 2016/20 A61K 31/444 (2006.01) A61K 31/497 (2006.01) A61K 31/506 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 11784873.9 C07D 401/14 C07D 403/04 C07D 407/14 (2006.01) C07D 413/14 (2006.01) C07D 417/04 (2006.01) C07D 417/14 (2006.01) (22) Date of filing: 02.11.2011 A61P 7/02 (2006.01) A61P 9/08 (2006.01) (86) International application number: PCT/US2011/058902 (87) International publication number: WO 2012/064559 (18.05.2012 Gazette 2012/20) (54) SGC STIMULATORS SGC-STIMULATOREN STIMULATEURS DE SGC (84) Designated Contracting States: • PERL, Nicholas, Robert AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Brookline GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO MA 02446 (US) PL PT RO RS SE SI SK SM TR • ROHDE, Jason Designated Extension States: Emeryville BA ME CA 94608 (US) (30) Priority: 09.11.2010 US 411730 P (74) Representative: Mullen, Lee Bryan et al 13.10.2011 US 201161546707 P Elkington and Fife LLP Thavies Inn House (43) Date of publication of application: 3-4 Holborn Circus 18.09.2013 Bulletin 2013/38 London EC1N 2HA (GB) (73) Proprietor: Ironwood Pharmaceuticals, Inc. (56) References cited: Cambridge, MA 02142 (US) EP-A1- 0 908 456 WO-A1-00/06568 WO-A1-93/11433 (72) Inventors: • KIM, Charles • SERGIEVSKII A V ET AL: "Reactivity of Cambridge 3,5-bis-(4-amino-1,2,5-oxadiazol-3-yl)-1,2 ,4-triaz MA 02139 (US) ole", RUSSIAN JOURNAL OF ORGANIC • NAKAI, Takashi CHEMISTRY, NAUKA/INTERPERIODICA, MO, Newton vol. 41, no. 2, 1 February 2005 (2005-02-01), pages MA 02458 (US) 261-267, XP019301931, ISSN: 1608-3393 • LEE, Thomas, Wai-ho Lexington MA 02420 (US) • MOORE, Joel Lexington MA 02421 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 637 659 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 2 637 659 B1 • TAKALO H ET AL: "DEVELOPMENT OF • JOHNSEN M ET AL: "New antithrombotic LUMINESCENT TERBIUM(III) CHELATES FOR 1-Phthalazinamines with Serotonin Antagonistic PROTEIN LABELLING: EFFECT OF Properties", ARCHIV DER PHARMAZIE, WILEY - TRIPLET-STATE ENERGY LEVEL", HELVETICA VCH VERLAG GMBH & CO. KGAA, DE, vol. 336, CHIMICA ACTA, VERLAG HELVETICA CHIMICA no. 12, 1 December 2003 (2003-12-01), pages ACTA, BASEL, CH, vol. 80, no. 2, 1 January 1997 591-597, XP003013892, ISSN: 0365-6233, DOI: (1997-01-01), pages372-387, XP009026448, ISSN: 10.1002/ARDP.200300775 0018-019X, DOI: 10.1002/HLCA.19970800204 2 EP 2 637 659 B1 Description CROSS REFERENCE TO RELATED APPLICATIONS 5 [0001] This patent application claims the benefits of U.S. Provisional Application Nos. 61/411,730 filed November 9, 2010 and 61/546,707 filed October 13, 2011. FIELD OF THE INVENTION 10 [0002] The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations thereof and the stimulators for use, alone or in combination with one or more additional agents, for treating and/or preventing various diseases, wherein an increase in the concentration of nitric oxide (NO) might be desirable. BACKGROUND OF THE INVENTION 15 [0003] Soluble guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) in vivo. sGC can be activated via both NO-dependent and NO-independent mechanisms. In response to this activation, sGC converts GTP into the sec- ondary messenger cyclic GMP (cGMP). The increased level of cGMP, in turn, modulates the activity of downstream effectors including protein kinases, phosphodiesterases (PDEs), and ion channels. 20 [0004] In the body, NO is synthesized from arginine and oxygen by various nitric oxide synthase (NOS) enzymes and by sequential reduction of inorganic nitrate. Three distinct isoforms of NOS have been identified: inducible NOS (iNOS or NOS II) found in activated macrophage cells; constitutive neuronal NOS (nNOS or NOS I), involved in neurotrans- mission and long term potentiation; and constitutive endothelial NOS (eNOS or NOS III) which regulates smooth muscle relaxation and blood pressure. 25 [0005] Experimental and clinical evidence indicates that reduced bioavailability and/or responsiveness to endogenous- ly produced NO contributes to the development of cardiovascular, endothelial, renal and hepatic disease, as well as erectile dysfunction. In particular, the NO signaling pathway is altered in cardiovascular diseases, including, for instance, systemic and pulmonary hypertension, heart failure, stroke, thrombosis and atherosclerosis. [0006] Pulmonary hypertension (PH) is a disease characterized by sustained elevation of blood pressure in the pul- 30 monary vasculature (pulmonary artery, pulmonary vein and pulmonary capillaries), which results in right heart hypertro- phy, eventually leading to right heart failure and death. In PH, the bioactivity of NO and other vasodilators such as prostacyclin is reduced, whereas the production of endogenous vasoconstrictors such as endothelin is increased, re- sulting in excessive pulmonary vasoconstriction. sGC stimulators have been used to treat PH because they promote smooth muscle relaxation, which leads to vasodilation. 35 [0007] Treatment with NO-independent sGC stimulators also promoted smooth muscle relaxation in the corpus cav- ernosum of healthy rabbits, rats and humans, causing penile erection, indicating that sGC stimulators are useful for treating erectile dysfunction. [0008] NO-independent, heme-dependent, sGC stimulators, such as those disclosed herein, have several important differentiating characteristics, including crucial dependency on the presence of the reduced prosthetic heme moiety for 40 their activity, strong synergistic enzyme activation when combined with NO and stimulation of the synthesis of cGMP by direct stimulation of sGC, independent of NO. The benzylindazole compound YC-1 was the first sGC stimulator to be identified. Additional sGC stimulators with improved potency and specificity for sGC have since been developed. These compounds have been shown to produce anti-aggregatory, anti-proliferative and vasodilatory effects. [0009] Since compounds that stimulate sGC in an NO-independent manner offer considerable advantages over other 45 current alternative therapies, there is a need to develop novel stimulators of sGC. They would be useful in the prevention, management and treatment of disorders such as pulmonary hypertension, arterial hypertension, heart failure, athero- sclerosis, inflammation, thrombosis, renal fibrosis and failure, liver cirrhosis, erectile dysfunction and other cardiovascular disorders. [0010] EP0908456A1 discloses pyrazoles linked to 5-membered ring heterocycles of general structure Formula A 50 which are sGC stimulators. 55 3 EP 2 637 659 B1 5 10 [0011] WO 00/06568A1 discloses compounds of general structural Formula B depicted below that are useful as cardiovascular agents and inhibit thrombocyte aggregation. 15 20 [0012] Johnson M et al: "New antithrombotic 1-Phthalazinamines with Serotonin Antagonist Properties", ARCHIV DER 25 PHARMAZIE, vol 336, no. 12, 1 December 2003, pages 591-597, XP003013892 describes nineteen 4-aryl and 4- arylalkyl-1-phthalazinamines with antithrombotic properties. These compounds are also serotonin receptor inhibitors. SUMMARY OF THE INVENTION 30 [0013] The present invention is directed to compounds according to Formula IA or IB, or a pharmaceutically acceptable salt thereof, 35 40 45 50 wherein: 55 the symbol with the encircled letter B represents ring B, and ring B is a phenyl or a 6-membered heteroaryl ring, containing 1 or 2 nitrogen ring atoms; n is an integer selected from 0 to 3; B B each J is independently selected from halogen, -CN, -NO2, a C1-6 aliphatic, -OR or a C3-8 cycloaliphatic group; 4 EP 2 637 659 B1 wherein each said C 1-6 aliphatic and each said C 3-8 cycloaliphatic group is optionally and independently substituted with up to 3 instances of R3; B each R is independently selected from hydrogen, a C 1-6 aliphatic or a C3-8 cycloaliphatic; wherein each said C1-6 3 aliphatic and each said C 3-8 cycloaliphatic ring is optionally and independently substituted with up to 3 instances of R ; 5 3 each R is independently selected from halogen, -CN, C 1-4 alkyl, C1-4 haloalkyl, -O(C 1-4 alkyl) or -O(C1-4 haloalkyl); X is selected from N, C-H or C, and is optionally substituted by JD when X is N or C; ring D is the 6-membered ring having X in Formula IA or the 5-membered ring having Y in Formula IB; each Y is independently selected from C-H, C, N, O or S, and is optionally substituted by J D when Y is C or N; each of the bonds between two adjacent Y atoms or between adjacent Y and N in Formula IB is independently a 10 single or double bond depending on whether Y is C, N, O or S; m is an integer selected from 0 to 3; D D each J is a substituent on a carbon or nitrogen ring atom and is independently selected from halogen, -NO 2, -OR , D D D D D d D d D D D -SR , -C(O)R , -C(O)OR , -C(O)N(R )2, -CN, -N(R )2,-N(R )C(O)R , -N(R )C(O)OR , -SO2R , -SO2N(R )2, d D D -N(R )SO2R , a C1-6 aliphatic, -(C1-6 aliphatic)-R , a C3-8 cycloaliphatic ring, a 6 to 10-membered aryl ring,
Load more

Recommended publications
  • United States Patent [19] [11] 15 Re. 30,811 Dykstra Et A1
    United States Patent [19] [11] 15 Re. 30,811 Dykstra et a1. [45] Reissued Dec. 1, 1981 [54] SUBSTITUTED PIPERIDINES 2,780,577 2/1957 Phillips et a]. .................. .. 424/267 THERAPEUTIC PROCESS AND 3,192,213 1/1965 Krapcho . .. 260/253 COMPOSITIONS 3,789,072 1/1974 Bernstein ...... .. 260/557 D 3,931,195 1/1976 Dykstra et a1. .............. .. 260/293.58 [75] Inventors: Stanley J. Dykstra; Joseph L. OTHER PUBLICATIONS Minielli, both of Evansville, Ind. 73 A. - ._ Mead J hnson 81 C a Lawson, J. Pharm. Ex p . Thera p ., 160, pp . 21-31 (1968). [ 1 ‘Slgnee Evansv?le in mm’ ‘W’ Krapcho et al., J. Med. Chem, 6, p. 219 (1963). ' Krapcho et al., J. Med. Chem, 7, pp. 376-377 (1964). [2!] Appl- NW 98.008 Krapcho et 31., .1. Med. Chem, 9, pp. 809-812 (1966). [22] Filed. No“ 28, 1979 Krapcho et al., J. Med. Chem, 12, pp. 164-166 (1969). Phillips, J. Am. Chem. Soc., 72, pp. 1850-1852 (1950). Related US. Patent Documents Primary Examiner—Stanley J. Friedman Reissue of. Attorney, Agent, or Firm-Robert H. Uloth; Robert E. [64] Patent NO.I 4,064,254 Camha" Issued: Dec. 20, 1977 [57] ABSTRACT F531:A 1. N 0 .: 0cL734,583 21 1976 The compounds are of the heterocycltc, class of 2 v _ ’ phenethylpiperidines having an amido substituent in the U-5- APPl1cat1°I151 ortho position of the phenethyl moiety. Substituents in 160] Dlvisio" 0151?’ NO- 620-207’ Ocl- 3» 19751 Pa" N°~ the ortho position include formamido, benzamido, cin 4‘00Oé143' wh‘ch '5 agd‘wls‘gn 025:", No- 384'34l' Jul" namamido, 2-thiophenecarboxamido, alkanesul 31' 1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Derivatives of Carboxylic Acid
    Derivatives of Carboxylic Acid acid chloride carboxylate nitrile amide acid anhydride ester Nomenclature of Acid Halides IUPAC: alkanoic acid → alkanoyl halide Common: alkanic acid → alkanyl halide I: 3-aminopropanoyl chloride I: 4-nitropentanoyl chloride c: b-aminopropionyl chloride c: g-nitrovaleryl chloride I: hexanedioyl chloride c: adipoyl chloride Rings: (IUPAC only): ringcarbonyl halide I: benzenecarbonyl bromide I: 3-cylcopentenecarbonyl chloride c: benzoyl bromide Nomenclature of Acid Anhydrides Acid anhydrides are prepared by dehydrating carboxylic acids acetic anhydride ethanoic acid ethanoic anhydride I: benzenecarboxylic anhydride I: butanedioic acid I: butanedioic anhydride c: benzoic andhydride c: succinic acid c: succinic anhydride Some unsymmetrical anhydrides I: ethanoic methanoic I: benzoic methanoic anhydride anhydride I: cis-butenedioic c: benzoic formic anhydride anhydride c: acetic formic anhydride Nomenclature of Esters Esters occur when carboxylic acids react with alcohols I: phenyl methanoate I: t-butyl benzenecarboxylate I: methyl ethanoate c: phenyl formate c: methyl acetate c: t-butyl benzoate I: isobutyl I: cyclobutyl 2- I: dimethyl ethanedioate cyclobutanecarboxylate methylpropanoate c: cyclobutyl a- c: dimethyl oxalate c: none methylpropionate Cyclic Esters Reaction of -OH and -COOH on same molecule produces a cyclic ester, lactone. To name, add word lactone to the IUPAC acid name or replace the -ic acid of common name with -olactone. 4-hydroxy-2-methylpentanoic acid lactone -methyl- -valerolactone Amides Product of the reaction of a carboxylic acid and ammonia or an amine. Not basic because the lone pair on nitrogen is delocalized by resonance. Classes of Amides 1 amide has one C-N bond (two N-H). 2 amide or N-substituted amide has two C-N bonds (one N-H).
    [Show full text]
  • Autonomic Nervous System Final.Pdf
    University of Hawai‘i Hilo Pre- Nursing Program NURS 203 – General AUTONOMIC NERVOUS SYSTEM Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the basic function of the autonomic nervous system (ANS) Know the neurotransmitters and receptors of each branch of the autonomic nervous system Understand if a tissue or organ is being activated by a certain branch of the ANS what the resulting action would be Understand how these two systems work in concert for daily living and situation of fight or flight 2 AUTONOMIC NERVOUS SYSTEM – WHERE IT FITS IN Nervous System Central Peripheral Somatic Autonomic (Skeletal Muscle) Parasympathetic Sympathetic Brain (cholinergic) ACh (adrenergic) NE Spinal Cord Nicotinic Alpha Beta α1, α2 β1, β2 Muscarinic 3 AUTONOMIC NERVOUS SYSTEM Fight or Flight Adrenergic Rest & Digest Norepinephrine Cholinergic Acetylcholine 4 AUTONOMIC NERVOUS SYSTEM – WHERE IT FITS IN Nervous System Central Peripheral Somatic Autonomic (Skeletal Muscle) Parasympathetic Sympathetic Brain (cholinergic) ACh (adrenergic) NE Spinal Cord Nicotinic Alpha Beta α1, α2 β1, β2 Muscarinic 5 AUTONOMIC NERVOUS SYSTEM (ANS) Parasympathetic NS Nicotinic Muscarinic Peripheral Sympathetic NS Alpha Autonomic Beta Nerves Parasympathetic Sympathetic Carrying ACh (cholinergic) ACh (adrenergic) NE Cholinergic Carrying NE Nicotinic Beta Adrenergic Alpha α1, α2 β1, β2 Muscarinic 6 AUTONOMIC NERVOUS SYSTEM (ANS) 7 AUTONOMIC NERVOUS SYSTEM (ANS) Ganglion: Group of nerve cell bodies. Connects pre and post ganglionic nerves. 8 AUTONOMIC NERVOUS SYSTEM (ANS) 9 AUTONOMIC NERVOUS SYSTEM (ANS) 10 AUTONOMIC NERVOUS SYSTEM (ANS) Preganglionic PNS ACh Preganglionic SNS ACh Post ganglionic Post ganglionic PNS SNS ACh NE 11 ACTIONS OF THE ANS - SNS Think fight or flight Dilate pupils Let in more light to see the bear Inhibit salivation This is no time to be hungry Relax airways Increase O2 intake Increase heart rate ….
    [Show full text]
  • General Prescription
    GENERAL PRESCRIPTION LESSON 1. INTRODUCTION. PRESCRIPTION. SOLID MEDICINAL FORMS Objective: To study the structure of the prescription, learn the rules and get practical skills in writing out solid medicinal forms in prescription. To carry out practical tasks on prescriptions it is recommended to use Appendix 1. Key questions: 1. Pharmacology as a science and the basis of therapy. Main development milestones of modern pharmacology. Sections of Pharmacology. 2. The concept of medicinal substance, medicinal agent (medicinal drug, drug), medicinal form. 3. The concept of the pharmacological action and types of the action of drugs. 4. The sources of obtaining drugs. 5. International and national pharmacopeia, its content and purpose. 6. Pharmacy. Rules of drug storage and dispensing. 7. Prescription and its structure. Prescription forms. General rules for writing out a prescription. State regulation of writing out and dispensing drugs. 8. Name of medicinal products (international non-proprietary name - INN, trade name). 9. Peculiarities of writing out narcotic, poisonous and potent substances in prescription. 10. Drugs under control. Drugs prohibited for prescribing. 11. Solid medicinal forms: tablets, dragee (pills), powders, capsules. Their characteristics, advantages and disadvantages. Rules of prescribing. Write out prescriptions for: 1. 5 powders of Codeine 0.015 g. 1 powder orally twice a day. 2. 10 powders of Didanosine 0.25 g in sachets to prepare solution for internal use. Accept inside twice a day one sachet powder after dissolution in a glass of boiled water. 3. 50 mg of Alteplase powder in the bottle. Dissolve the content of the bottle in 50 ml of saline. First 15 ml introduce intravenously streamly, then intravenous drip.
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Use of Non-Selective Β-Blockers Is Associated with Decreased Tumor Proliferative Indices in Early Stage Breast Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 4), pp: 6446-6460 Research Paper Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer Alexa Montoya1,2,*, Clarissa N. Amaya1,*, Andres Belmont3,*, Nabih Diab3, Richard Trevino3, Geri Villanueva3, Steven Rains1, Luis A. Sanchez4, Nabeel Badri4, Salman Otoukesh4, Ali Khammanivong5, Danielle Liss4, Sarah T. Baca6, Renato J. Aguilera6, Erin B. Dickerson5,7, Alireza Torabi3,8, Alok K. Dwivedi1,3,9, Aamer Abbas3,4, Karinn Chambers3,10, Brad A. Bryan1,3, Zeina Nahleh3,4 1Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, Texas, USA 2Department of Biology, University of Texas, El Paso, Texas, USA 3Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas, USA 4Department of Hematology/Oncology, Loma Linda University Health Sciences Center, Loma Linda, California, USA 5Department of Veterinary Clinical Sciences, University of Minnesota, Saint Paul, Minnesota, USA 6Border Biomedical Research Center, University of Texas, El Paso, Texas, USA 7Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA 8Department of Pathology, Texas Tech University Health Sciences Center, El Paso, Texas, USA 9Division of Biostatistics and Epidemiology, Texas Tech University Health Sciences Center, El Paso, Texas, USA 10Department of Surgery, Texas Tech University Health Sciences Center, El Paso, Texas, USA *These authors contributed equally to this work Correspondence to: Zeina Nahleh, email: [email protected] Brad A. Bryan, email: [email protected] Keywords: beta blocker, propranolol, breast cancer, proliferation, Ki-67 Received: September 07, 2016 Accepted: December 13, 2016 Published: December 23, 2016 ABSTRACT Previous studies suggest beta-adrenergic receptor (β-AR) antagonists (β-blockers) decrease breast cancer progression, tumor metastasis, and patient mortality; however the mechanism for this is unknown.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0022773 A1 Bruncko Et Al
    US 2010.0022773A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0022773 A1 Bruncko et al. (43) Pub. Date: Jan. 28, 2010 (54) APOPTOSIS PROMOTERS (22) Filed: Feb. 23, 2009 (76) Inventors: Milan Bruncko, Green Oaks, IL Related U.S. Application Data (US); Hong Ding, Gurnee, IL (US); (63) Continuation of application No. 1 1/127,940, filed on Steven Elmore, Gurnee, IL (US); May 12, 2005, which is a continuation-in-part of appli Aaron Kunzer, Schaumburg, IL cation No. 10/988,388, filed on Nov. 12, 2004, now (US); Christopher L. Lynch, abandoned. Trevor, WI (US); William McClellan, Waukegan, IL (US); (60) Provisional application No. 60/519,695, filed on Nov. Cheol-Min Park, Gurnee, IL (US); 13, 2003. Andrew Petros, Mundelein, IL (US); Xiaohong Song, Grayslake, Publication Classification IL (US); Noah Tu, Gurnee, IL (US); (51) Int. C. Xilu Wang, Oakwood, IL (US); C07D 24I/04 (2006.01) Michael Wendt, Vernon Hills, IL (US) (52) U.S. Cl. ........................................................ 544/392 Correspondence Address: (57) ABSTRACT PAUL. D. YASGER Disclosed are compounds which inhibit the activity of anti ABBOTT LABORATORIES apoptotic protein family members, compositions containing 100 ABBOTT PARK ROAD, DEPT. 377/AP6A the compounds and uses of the compounds for preparing ABBOTT PARK, IL 60064-6008 (US) medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein (21) Appl. No.: 12/390,945 family member. US 2010/0022773 A1 Jan. 28, 2010 APOPTOSIS PROMOTERS or N(CH)SO.N(CH) R', and the remainder are indepen dently selected H, F, Cl, Br, I, CF, C(O)OH, C(O)NH2 or 0001.
    [Show full text]
  • Influence of Obesity and Exercise
    nutrients Article β2 Adrenergic Regulation of the Phagocytic and Microbicide Capacity of Circulating Monocytes: Influence of Obesity and Exercise 1,2, 2,3, 2,4 Isabel Gálvez y , Leticia Martín-Cordero y , María Dolores Hinchado and Eduardo Ortega 2,4,* 1 Grupo de Investigación en Inmunofisiología, Departamento de Enfermería, Facultad de Medicina, Universidad de Extremadura, 06071 Badajoz, Spain; [email protected] 2 Instituto Universitario de Investigación Biosanitaria de Extremadura (INUBE), 06071 Badajoz, Spain; [email protected] (L.M.-C.); [email protected] (M.D.H.) 3 Grupo de Investigación en Inmunofisiología, Departamento de Enfermería, Centro Universitario de Plasencia, Universidad de Extremadura, 10600 Plasencia, Spain 4 Grupo de Investigación en Inmunofisiología, Departamento de Fisiología, Facultad de Ciencias, Universidad de Extremadura, 06071 Badajoz, Spain * Correspondence: [email protected]; Tel.: +34-924-289-300 These authors contributed equally to this work. y Received: 19 March 2020; Accepted: 13 May 2020; Published: 16 May 2020 Abstract: Obese individuals present anomalous immune/inflammatory responses with dysregulations in neuroendocrine responses and immune/stress feedback mechanisms. In this context, exercise and β2 adrenergic activation present monocyte-mediated anti-inflammatory effects that are modulated by obesity. However, these anti-inflammatory effects could immunocompromise the monocyte-mediated innate response against a pathogen challenge. Thus, the objective of this work was to evaluate the effect of obesity, and exercise in this condition, on the β2 adrenergic regulation of the phagocytic and microbicide capacity of circulating monocytes. C57BL/6J mice were allocated to different sedentary or exercised, lean or obese groups. Obese mice showed a lower monocyte-mediated innate response than that of lean mice.
    [Show full text]
  • Developing Novel Therapeutic Agents for Acanthamoeba Infection and Investigating the Process of Encystment
    Developing novel therapeutic agents for Acanthamoeba infection and investigating the process of encystment Anas Abdullah Hamad (BSc, MSc) A thesis submitted in partial fulfilment of the requirements of the University of Wolverhampton for the degree of Doctor of Philosophy June 2020 Declaration This work or any part thereof has not previously been presented in any form to the University or to any other body whether for the purposes of assessment, publication or for any other purpose (unless otherwise indicated in page 3). Save for any express acknowledgements, references and/or bibliographies cited in the work, I confirm that the intellectual content of the work is the result of my own efforts and of no other person. The right of Anas Abdullah Hamad to be identified as author of this work is asserted in accordance with ss.77 and 78 of the Copyright, Designs and Patents Act 1988. At this date copyright is owned by the author. Signature………………………………………. Date……………………………………………. 15/10/2020 2 List of posters and publication related to the work presented in this thesis: Heaselgrave, W., Hamad, A., Coles, S. and Hau, S., 2019. In Vitro Evaluation of the Inhibitory Effect of Topical Ophthalmic Agents on Acanthamoeba Viability. Translational vision science & technology, 8(5), pp.17-17. Manuscript published. Hamad, A. and Heaselgrave, W., 2017. Developing novel treatments for the blinding protozoan eye infection Acanthamoeba keratitis. Proceedings of the Internal Annual Research Symposium, Poster no. 23, University of Wolverhampton, UK. Hamad, A. and Heaselgrave, W., 2018. Developing new treatments and optimising existing treatment strategies for the corneal infection Acanthamoeba keratitis.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Olodaterol Exerts Anti-Inflammatory Effects on COPD Airway Epithelial Cells
    Yang et al. Respir Res (2021) 22:65 https://doi.org/10.1186/s12931-021-01659-2 RESEARCH Open Access Olodaterol exerts anti-infammatory efects on COPD airway epithelial cells Nan Yang1† , Gurpreet K. Singhera1†, Yi Xuan Yan1, Michael P. Pieper2, Janice M. Leung1, Don D. Sin1 and Delbert R. Dorscheid1* Abstract Background: Airway infammation is a key feature of chronic obstructive pulmonary disease (COPD) and inhaled corticosteroids (ICS) remain the main treatment for airway infammation. Studies have noted the increased efcacy of ICS and long-acting beta 2 agonist (LABA) combination therapy in controlling exacerbations and improving airway infammation than either monotherapy. Further studies have suggested that LABAs may have inherent anti-infamma- tory potential, but this has not been well-studied. Objective: We hypothesize that the LABA olodaterol can inhibit airway infammation resulting from exposure to respiratory syncytial virus (RSV) via its binding receptor, the β2-adrenergic receptor. Methods: Human bronchial epithelial brushing from patients with and without COPD were cultured into air–liquid interface (ALI) cultures and treated with or without olodaterol and RSV infection to examine the efect on markers of infammation including interleukin-8 (IL-8) and mucus secretion. The cell line NCI-H292 was utilized for gene silencing of the β2-adrenergic receptor via siRNA as well as receptor blocking via ICI 118,551 and butaxamine. Results: At baseline, COPD-ALIs produced greater amounts of IL-8 than control ALIs. Olodaterol reduced RSV- mediated IL-8 secretion in both COPD and control ALIs and also signifcantly reduced Muc5AC staining in COPD-ALIs infected with RSV.
    [Show full text]